Hyperkalaemia formulary options (Formulary: Fluids & electrolytes)

Important: Formulation and dosage details

Formulation:

• Powder for oral suspension 5g, 10g (Restricted: as per indication below)

Indications: 

• As per SMC 2288: Treatment of [chronic] hyperkalaemia in adult patients. (Restricted: Specialist recommendation only)
  SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0 mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).
• As per SMC 2515: For the treatment of [acute] hyperkalaemia in adult patients. (Restricted: Specialist use only)
  SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.

Monitoring: Serum potassium should be monitored regularly during treatment when clinically indicated, including after changes to products affecting the serum potassium concentration (e.g. renin-angiotensin-aldosterone system (RAAS) inhibitors or diuretics) and after dose titration. See: Summary of product characteristics (emc)